About Relypsa
Relypsa is a company based in Redwood City (United States) founded in 2007 was acquired by Galenica in July 2016. Relypsa has raised $207.43 million across 9 funding rounds from investors including Credit Suisse, New Leaf Venture Partners and Orbimed. The company has 284 employees as of December 31, 2020. Relypsa operates in a competitive market with competitors including Calliditas Therapeutics, Tenaya Therapeutics, Cellino, MyoKardia and Eiger BioPharmaceuticals, among others.
- Headquarter Redwood City, United States
- Employees 284 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$207.43 M (USD)
in 9 rounds
-
Latest Funding Round
$150 M (USD), Debt – Conventional
May 03, 2016
-
Investors
Credit Suisse
& 10 more
-
Employee Count
284
as on Dec 31, 2020
-
Acquired by
Galenica
(Jul 21, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Relypsa
Relypsa has successfully raised a total of $207.43M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $150 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Relypsa
Relypsa has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Credit Suisse, New Leaf Venture Partners and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Healthcare royalty investments are focused on US and UK markets.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Relypsa
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Relypsa
Investment portfolio details for Relypsa
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Relypsa
Detailed financials for Relypsa
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Relypsa Comparisons
Peer comparison for Relypsa
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Relypsa
Relypsa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Tenaya Therapeutics, Cellino, MyoKardia and Eiger BioPharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
Detailed competitors of Relypsa
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Relypsa
Complete news archive for Relypsa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Relypsa
Relypsa was founded in 2007.
Relypsa is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Relypsa is a funded company, having raised a total of $207.43M across 9 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Relypsa is 284.
Relypsa was founded in 2007 and is headquartered in Redwood City, United States. Focus is placed on the development of novel non-absorbed polymeric drugs targeted at cardiovascular and renal diseases. Operations center on creating therapies for conditions such as hyperkalemia. The lead product, Veltassa (patiromer) for oral suspension, serves as a non-absorbed potassium binder for managing elevated potassium levels in patients.
Relypsa's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Relypsa has 11 investors. Key investors include Credit Suisse, New Leaf Venture Partners, Orbimed, Galenica, and Athyrium Capital Management.